Document Type

Article

Publication Date

2-12-2018

JAX Source

Nat Commun 2018 Feb 12; 9(1):621

PMID

29434196

DOI

https://doi.org/10.1038/s41467-018-03061-x

Abstract

Albumin and IgG have remarkably long serum half-lives due to pH-dependent FcRn-mediated cellular recycling that rescues both ligands from intracellular degradation. Furthermore, increase in half-lives of IgG and albumin-based therapeutics has the potential to improve their efficacies, but there is a great need for robust methods for screening of relative FcRn-dependent recycling ability. Here, we report on a novel human endothelial cell-based recycling assay (HERA) that can be used for such pre-clinical screening. In HERA, rescue from degradation depends on FcRn, and engineered ligands are recycled in a manner that correlates with their half-lives in human FcRn transgenic mice. Thus, HERA is a novel cellular assay that can be used to predict how FcRn-binding proteins are rescued from intracellular degradation. Nat Commun 2018 Feb 12; 9(1):621.

Comments

Open access under Creative Commons Attribution (CC BY) license (Creative Commons Attribution 4.0 International License).

Share

COinS